U.S. Defense Logistics Agency Exercises 1-Year Option Period in Applied DNA Counterfeit Mitigation Contract

STONY BROOK, NY / ACCESSWIRE / July 18, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN), a leader in PCR-based DNA technologies, announced that the U.S. Defense Logistics Agency (DLA) has exercised the first one-year option period of a three-year base contract. This contract, originally entered into in May 2021, includes two one-year option periods and supports DLA's counterfeit mitigation initiatives for FSC 5962 microcircuits. The contract's maximum value is $1.04 million over a potential five-year term.

The option-year exercise continues Applied DNA's support for DLA's counterfeit mitigation program, which began in 2014. Judy Murrah, chief operating officer of Applied DNA, stated, "We are pleased to enable DLA to maintain program continuity in service of the nation’s defense capabilities and further reinforce the application of our forensic DNA mark as a secure, high-resolution taggant to track provenance and ensure authenticity."